CS15-openlabel extension trial (Recruiting)
An open-label extension study of olezarsen (ISIS678354) administered subcutaneously to patients with severe hypertriglyceridemia (SHTG)
- Medicine
- olezarsen
- Population
- Primairy prevention cardiovasular disease
- Phase
- 3
- Starting year
- 2023